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Calcium-binding domains in the α-subunit of integrins contain
a central loop structure. To examine the importance of the loop
structure, a series of αIIb mutants containing changes to the cal-
cium-liganding amino acids have been constructed. Significantly,
none of the mutant αIIbβ3 complexes was detected on the surface
of transfected cells, but mutant pro-αIIb was detected in cell
lysates in complex with β3. To study the importance of the
regions flanking the second calcium-binding domain for ligand-
binding and ligand-binding specificity, three αIIb/α5 chimaeras
containing α5 sequences flanking or flanking and including the
second calcium-binding domain were constructed. The chimaera
containing both α5-flanking regions was not expressed on the cell
surface, but FR1 and FR2, substituting either the first or second
flanking region, were expressed. FR1β3-transfected cells lost the
ability to adhere to fibrinogen and to support aggregation and had
minimal fibrinogen-binding ability. The heterodimer complex was
less stable than the wild-type. FR2β3-transfected cells adhered to
fibrinogen and bound soluble fibrinogen with higher affinity when
compared with wild-type. In addition, the heterodimer complex
was more stable than wild-type. These results indicate that the
conformation of the second calcium-binding domain is critical
for maturation of the αIIbβ3 complex and expression on the cell
surface and that the surrounding sequences are critical for αIIbβ3
function.
Key words: calcium-binding domain, fibrinogen, integrin αIIbβ,
integrin αIIbβ3, platelet.
INTRODUCTION
Integrins are a family of heterodimeric cell-surface proteins,
which mediate cell–cell and cell–extracellular matrix and cell–
soluble ligand interactions [1]. The platelet integrin αIIbβ3
(GPIIb-IIIa) is the major cell-surface protein at approx.
80 000 copies/platelet [2], representing approx. 15 % of the sur-
face protein [3]. αIIbβ3 plays an essential role in primary haemo-
stasis, mediating platelet–platelet and platelet–subendothelial
matrix interactions through the binding of its ligands fibrinogen,
von Willebrand factor, fibronectin and vitronectin [4,5].
Integrins are synthesized from separate gene products on
chromosome 17 [6,7] in the calcium-rich environment of the endo-
plasmic reticulum, where αIIb is synthesized as a single poly-
peptide chain precursor of Mr 145 000 and forms a non-covalent
heterodimer with the β3-subunit [8–11]. Preliminary glycosyl-
ation takes place before the heterodimer is transported to the
Golgi apparatus, where endoproteolytic cleavage of αIIb into
disulphide-bonded heavy and light chains and oligosaccharide
processing to complex carbohydrates occurs [11,12].
Each of the α- and β-subunits consists of a large extracellular
domain, a transmembrane region and a short (except for β4)
cytoplasmic tail. The α-subunits contain four highly conserved
bivalent cation-binding domains that were originally modelled
to be structurally similar to the ‘EF-hand’ motif found in
calmodulin and other proteins [13,14], but are now modelled to
be nine-aminoacid β-hairpin loops with the consensus sequence
Asp-Hpb-Asp/Asn-Xaa-Asp/Asn-Gly-Hpb-Xaa-Asp, where Hpb
Abbreviations used: CHO, Chinese-hamster ovary-K1; DMEM, Dulbecco’s modified Eagle’s medium; DTT, dithiothreitol; HRP, horseradish peroxidase;
mAb, monoclonal antibody; WT, wild-type.
1 To whom correspondence should be addressed, at 932 Mary Ellen Jones Bldg., CB 7035, Chapel Hill, NC 27599-7035, U.S.A. (e-mail gidwitz@med.
unc.edu).
represents a hydrophobic residue [15,16]. Both heterodimer
association and ligand binding are dependent on bivalent-cation
binding [17,18]. Calcium binds to the α-subunit of αIIbβ3, and
high-affinity binding of fibrinogen requires that all four calcium-
binding sites be occupied [19].
Using structural modelling, Springer [15] proposed a β-pro-
peller secondary structure for the N-terminal approx. 440 amino
acids of α-integrins. The model consists of a circular array of
seven repeats of four β-strands separated by loops. In this model,
ligand and Mg2+ binding are predicted to be on the upper face
of the β-propeller, whereas the four calcium-binding domains are
proposed to lie in loops between strands 1 and 2 of repeats 4–7
and be orientated near the bottom of the propeller. This model has
been recently confirmed by the solving of the crystal structure of
extracellular domain of the αVβ3 complex [16].
Although the β-propeller model and crystal structure model li-
gand binding to be at the interface of the upper surface of the
β-propeller and the β-subunit, compelling evidence has also im-
plicated the second calcium-binding domain of αIIb, amino acids
296–314, as being important in the ligand binding. Chemical
cross-linking of the fibrinogen γ -chain C-terminal peptide, fol-
lowed by proteolysis, identified the second calcium-binding do-
main as a critical region for binding the peptide [20]. High-affinity
binding of the peptide required calcium and that αIIbβ3 be in the
activated conformation [21]. Peptides corresponding to amino
acids 296–306 or 300–312 blocked platelet aggregation and di-
rectly bound to fibrinogen. Moreover, antibodies against αIIb296-306
blocked binding of fibrinogen to the peptide and to αIIbβ3
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[22,23]. In a previous study [24], we showed that chimaeric re-
ceptors in which all or parts of the second calcium-binding
domain were replaced with the highly homologous α5 sequence
demonstrated no difference in expression or function of the
receptor. In the present study, we have examined the importance of
the calcium-binding loop structure and surrounding sequences on
protein expression and function by constructing a series of point
mutations in the second calcium-binding domain of αIIb and by
making chimaeras with α5 that contained the second calcium-
binding domain and the sequences flanking it, or just each of the
flanking sequences.
MATERIALS AND METHODS
Construction of mutant αIIb cDNA clones
To facilitate cloning, the NotI–ClaI fragment of αIIb was sub-
cloned into Bluescript II KS and named BSIIbN/C. All mutants
were constructed using a PCR mutagenesis technique. For all mu-
tations, the upstream primer was the mutagenic primer. Mutagenic
oligonucleotides created the amino acid change(s) designated in
the name of the clone and contained a restriction site near the 5′-
end of the oligonucleotide unique to the BSIIbN/C. For D297A
(Asp297 → Ala), N299A, D297A-N299A and D297Q-N299Q, the
mutagenic oligonucleotide spanned the BsmI site at nt 964 of
αIIb. For D301A and D305A, the oligonucleotide spanned the
AatII site at nt 987. The downstream primer spanned the ClaI site
at nt 1374. The PCR product was digested with either BsmI or
AatII and ClaI and subcloned into BSIIbN/C.
αIIb/α5(254-348) was constructed by ligating a PCR product from
αIIb with one from α5. The αIIb PCR product spanned the PmlI
site at nt 737 and made two silent mutations to create an AscI site
at base 859, bordering the upstream non-conserved region flank-
ing the second calcium-binding domain. The α5 PCR product
contained an AscI near the 5′-end, followed immediately by an α5
sequence from nt 906–1190. A silent mutation was introduced at
nt 1191 to destroy the XcmI site. The 3′-end of the PCR product
matched the sequence of αIIb from nt 1154–1185, including the
XcmI site at nt 1170. The PCR products were digested with PmlI
and AscI or AscI and XcmI respectively, and ligated into BSIIbN/C
that had been digested with PmlI and XcmI.
FR1 was constructed by ligating the αIIb PmlI–AscI PCR
product with a PCR product of α5 that spanned the AscI site
and bases 906–977, followed by αIIb sequence from nt 938 to the
BsmI site at nt 964 of αIIb into BSIIbN/C that had been digested
with PmlI and BsmI. FR2 was similarly constructed using an αIIb
PCR product that spanned the BsmI site through the HaeII site
at nt 1019 and an α5 PCR product that included αIIb sequence
from the HaeII site through nt 1038 and then α5 sequence through
the XcmI site, as above. The appropriately digested PCR products
were ligated into BSIIbN/C that had been digested with HaeII and
XcmI. The sequence of each of the mutant clones was confirmed,
and the NotI–ClaI fragment of each mutant was then subcloned
into wild-type pRcCMVαIIb [24].
Cell culture and transfections
COS-7 cells were obtained from the UNC Tissue Culture Facility
and maintained in DMEM (Dulbecco’s modified Eagle’s medium;
high glucose formula) containing 10 % (v/v) foetal bovine serum
and 1 % penicillin and streptomycin. Wild-type or mutant con-
structs were co-transfected with pcDNA1/Ampβ3E, a β3
construct containing a silent mutation to remove the internal
EcoRI site, into COS-7 cells using LIPOFECTAMINETM (Gibco
BRL, Gaithersburg, MD, U.S.A.) as described previously [24].
CHO (Chinese-hamster ovary-K1) cells were maintained and
transfected by electroporation as described previously [25].
Antibodies
The mAb (monoclonal antibody) Tab, [26], specific for αIIb,
was provided by R. P. McEver (University of Oklahoma Health
Sciences Center, Oklahoma City, OK, U.S.A.). The mAb B1B5
[27], which recognized a membrane-proximal epitope on αIIb,
was provided by J. S. Bennett (University of Pennsylvania,
Philadelphia, PA, U.S.A.). Anti-β3 mAb AP3 [28] and rabbit
polyclonal anti-αIIb SEW-8 were provided by P. J. Newman
(Blood Center of Southeastern Wisconsin, Milwaukee, WI,
U.S.A.). The αIIbβ3-complex-specific mAbs AP2 [29], 10E5
[30] and A2A9 [31] were supplied by T. J. Kunicki (Scripps
Research Institute, La Jolla, CA, U.S.A.), B. S. Coller (Albert
Einstein University, New York, NY, U.S.A.) and J. S. Bennett
respectively. The activating mAb LIBS 6, specific for β3 [32],
was supplied by M. H. Ginsberg (Scripps Research Institute).
PAC-1 murine IgM [33] was from University of Pennsylvania
Cell Center (Philadelphia, PA, U.S.A.). FITC–PAC-1 was from
BD Biosciences (San Jose, CA, U.S.A.). mAbs against synthetic
peptides containing the N- and C-terminal fibrinogen Aα RGD
motifs (Aα 87–100 and Aα 566–680 respectively) were provided
by Z. M. Ruggeri (Scripps Research Institute) [34]. mAb 4A5 [35]
against the fibrinogen γ -chain H12 sequence was provided by
G. R. Matsueda (Bristol–Myers Squibb Pharmaceutical Research
Institute, Princeton, NJ, U.S.A.). Function-blocking anti-hamster
α5β1 mAb PB1 [36] was a gift from R. L. Juliano (University of
North Carolina). HRP (horseradish peroxidase)-conjugated goat
anti-rabbit IgG was from Sigma (St. Louis, MO, U.S.A.). FITC-
goat anti-mouse IgG and rabbit anti-mouse IgM were from Zymed
(San Francisco, CA, U.S.A.), FITC-chicken anti-fibrinogen was
from Biopool International (Ventura, CA, U.S.A.); rabbit anti-
fibronectin was from Chemicon International (Temecula, CA,
U.S.A.). R-phycoerythrin-conjugated donkey anti-rabbit IgG
F(ab′)2 was from Jackson Immunoresearch (West Grove, PA,
U.S.A.).
Immunoprecipitation
Cells were immunoprecipitated essentially as described pre-
viously [24]. Briefly, cells were solubilized in a buffer containing
1 % Nonidet P40 (Sigma) and protease inhibitors. Cellular debris
was removed by centrifugation and lysates were precleared with
normal mouse serum (Sigma) and GammaBind Plus Sepharose
(Amersham Biosciences, Piscataway, NJ, U.S.A.). Cleared lysates
were incubated for 1 h at 4 ◦C with the indicated mAb, followed
by GammaBind Plus Sepharose and then washed five times in
50 mM Tris/HCl (pH 8), 0.5 % Nonidet P40 and 0.5 M NaCl.
Before lysis, a portion of the cells was incubated with
NHS-LC-biotin [succinimidyl-6-(biotinamido)hexanoate; Pierce,
Rockford, IL, U.S.A.] to label the cell-surface proteins as des-
cribed previously [24]. Biotinylated immunoprecipitates were
separated on 7.5 % non-reducing SDS/polyacrylamide gel,
electrotransferred to nitrocellulose (Costar, Cambridge, MA,
U.S.A.), detected with streptavidin–HRP (Gibco BRL) and
visualized by chemiluminescence using either ECL® or ECL
PlusTM (Amersham Biosciences) or SuperSignalTM CL-HRP
(Pierce). Unlabelled proteins were separated by SDS/PAGE
(7.5 % gel) under reducing conditions, transferred to either
nitrocellulose or PVDF (Millipore, Bedford, MA, U.S.A.),
immunodetected with SEW-8 followed by goat anti-rabbit-HRP
and visualized by chemiluminescence. Biotinylated molecular-
mass standards (Sigma) were included on gels.
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Flow cytometry
Flow-cytometric analysis was performed as described previously
[25]. Briefly, cells were harvested, washed and resuspended
in PBC [PBS containing 2 % (w/v) BSA, 0.1 mM CaCl2 and
0.1 mM MgCl2]. Cells were incubated at the indicated temper-
ature for the indicated time with the indicated antibody, washed,
incubated with FITC-goat anti-mouse IgG, washed, fixed with
paraformaldehyde and analysed on a flow cytometer. PAC-1-
binding studies were conducted as described previously [24]
using unlabelled PAC-1 and FITC-rabbit anti-mouse IgM or
with FITC–PAC-1, except that cells were activated either by
incubation with DTT (dithiothreitol) or with LIBS 6. For studies
on subunit dissociation, cells were harvested and washed and then
resuspended in PBS containing 2 % BSA. Immediately before the
start of the experiment, EDTA was added to a final concentration
of 5 mM. Cells were incubated at the indicated temperature for
the indicated times, and then immediately diluted 10-fold with
PBS, centrifuged and resuspended in PBC containing the αIIbβ3-
complex-specific mAb AP2 and processed as above.
Adhesion
Adhesion was performed as described previously [24]. Fibrinogen
was either purified from fresh-frozen plasma using the glycine-
precipitation method of Kazal et al. [37] or purchased from
Enzyme Research Laboratories (South Bend, IN, U.S.A.).
Fibrinogen was treated with gelatin–agarose three times (Sigma)
to remove contaminating fibronectin. For adhesion studies, flat-
bottomed immunoassay plates (Costar, Corning, Acton, MA,
U.S.A.) were incubated overnight at 4 ◦C either with 10 µg/
ml fibronectin (Collaborative Biomedical Products, Becton
Dickinson, Bedford, MA, U.S.A.) or with the indicated con-
centration of fibrinogen and then blocked with heat-inactivated
BSA. Cells (1 × 105) were allowed to adhere to wells of the ligand-
coated plates for 2 h at 37 ◦C. Plates were washed, stained with
Crystal Violet and absorbance was determined at 540 nm. Non-
specific binding was defined as binding to heat-inactivated BSA-
coated wells. When present, the peptide GRGDSF (University
of North Carolina Protein Chemistry Laboratory) was incubated
with the cells for 30 min before plating.
Fibrinogen and fibronectin binding
Immediately before use, fibrinogen was centrifuged at 14 000 g
for 5 min to reduce the potential amount of fibrin in the prepar-
ation. For fibrinogen-binding studies, cells were resuspended in
DMEM + 20 mM Hepes (pH 7.5), LIBS 6 ascites at a 1:100 dilu-
tion and either 1 mM GRGDSF or buffer. Cells were incubated at
room temperature (23 ◦C) for 15 min before the addition of FITC-
fibrinogen [24]. Cells were incubated at room temperature for
30 min, washed, fixed and analysed by flow cytometry. Specific
binding was defined as the difference in mean fluorescent intensity
between cells incubated in the presence and absence of GRGDSF.
Results were fitted to the 1-site ligand-binding equation, y =
a0x/(a1 + x). To test the effect of the anti-N-terminal and anti-
C-terminal fibrinogen Aα RGD motif and anti-γ chain antibodies,
cells were resuspended in Hepes/Tyrode’s buffer without calcium
or magnesium that had been treated with Chelex-100 (Bio-Rad,
Hercules, CA, U.S.A.). Calcium was added to a final concentration
of 2 mM. Cells were incubated with LIBS 6 and either 1 mM
GRGDSF or buffer for 15 min at room temperature before the
addition of 50 nM fibrinogen and 10 µg/ml anti-fibrinogen N-
terminal-Aα antibody, anti-C-terminal-Aα RGD antibody, anti-γ -
chain H12 antibody or control IgG, all of them purified earlier
from ascites on GammaBind Sepharose. Cells were incubated at
22 ◦C for 30 min, washed and then incubated with FITC-chicken
anti-human fibrinogen. Cells were washed, fixed and analysed by
flow cytometry as above.
Fibronectin binding was measured by resuspending harvested
cells in Hepes/Tyrode’s containing 1 mM MnCl2. Cells were
incubated with 66 µg/ml PB1 and 1 mM GRGDSF, 31 µM cyclic
RGDFV (Bachem, Torrance, CA, U.S.A.; underlining indicates
the D form) or buffer for 15 min before addition of 100 nM
fibronectin. Cells were incubated at room temperature for 30 min,
washed and incubated with rabbit anti-fibronectin followed by R-
phycoerythrin-conjugated donkey anti-rabbit IgG F(ab′)2, fixed
and analysed by flow cytometry.
Aggregation
Aggregation was performed essentially as described previously
[24]. Cells were harvested, washed and resuspended at 2 ×
107 cells/ml in Hepes/Tyrode’s (pH 7.4) containing 1 mM MnCl2,
but without calcium or magnesium, and incubated with 1 mM
GRGDSF or buffer for 15 min at room temperature. Fibrinogen
was added to a final concentration of 0.25 mg/ml, and cells were
incubated on a gyratory shaker at 75 rev./min for 30 min at room
temperature and then photographed.
Molecular modelling
Models of wild-type αIIb, FR1 and FR2 were built and optimized
using the Modeler module of the InsightII 2000 molecular
modelling system from Accelrys (http://www.accelrys.com).
Sequences for α5 (human, mouse and frog), αV (human, bovine,
mouse, chick, newt and frog), α8 (human, mouse and chick) and
αIIb (human, mouse, dog, rabbit, pig, horse and yellow baboon)
from the RGD group of integrins were obtained from Swiss-Prot
and TrEMBL [38] and aligned using ClustalX [39]. The structural
template used for modelling was the αV chain of the crystal
structure of the αVβ3 complex (PDB Identifier 1JV2) [16]. Panels
in Figures 1, 10 and 11 were created with SPOCK [40] and
rendered with MOLSCRIPT [41] and Raster3D [42,43].
RESULTS
Expression of calcium-binding domain mutant complexes
We prepared a series of mutant αIIb DNAs encoding single amino
acid changes at the calcium liganding sites, substituting Ala or
Gln for the wild-type Asp or Asn, creating the following mutant
αIIb constructs: D297A, N299A, D301A and D305A, and double
mutants, D297A-N299A and D297Q-N299Q (Figure 1). αIIb mu-
tants were transiently co-expressed with β3 and cell-surface
expression was examined by immunoprecipitation of biotinylated
cell-surface proteins with antibodies to αIIb. Bands corresponding
to αIIb and β3 were detected in cells transfected with wild-type
αIIb, but no bands were seen in mock-transfected cells, cells
transfected with β3 only or cells transfected with any of the
mutants (Figure 2A, lanes 1–9), indicating that mutant αIIbβ3
constructs were not expressed on the cell surface.
Unlabelled cell lysates were immunoprecipitated with B1B5,
an mAb to a membrane-proximal epitope of αIIb that is not altered
by the mutations, to evidence intracellular protein expression. As
can be seen in Figure 2(B), no protein was detected in mock-
transfected cells or cells transfected with β3 only. Cells trans-
fected with wild-type αIIb expressed both mature and pro-αIIb,
the uncleaved precursor to αIIb. Each of the mutant transfectants
expressed pro-αIIb in quantities similar to cells expressing wild-
type αIIbβ3, but did not express any of the mature form.
c© 2004 Biochemical Society
452 S. Gidwitz, B. Temple and G. C. White, II
Figure 1 Model of αIIb β-propeller depicting location of second calcium-binding domain point mutations and flanking regions 1 and 2 (FR1 and FR2)
(A) Side view of β-propeller blades 4–6 (dark green, dark plum and violet respectively). Calcium co-ordinating amino acids that were mutated are depicted as light blue balls. Light green indicates
FR1 and light plum indicates FR2. Gold balls indicate calcium atoms. (B) Bottom view of β-propeller. Colours as in (A).
Figure 2 Expression, processing and complex formation of mutant integrins
Cells were transiently co-transfected with WT (wild-type) or mutant α-subunit and with β3, and
after 72 h they were analysed for cell surface and cellular expression of integrins. (A) Cell-surface
proteins were biotinylated and immunoprecipitated with anti-αIIb mAb B1B5, electrophoresed
and detected with streptavidin–HRP as described in the Materials and methods section. 1, mock;
2, β3; 3, WT; 4, D297A-N299A; 5, D297Q-N299Q; 6, D297A; 7, N299A; 8, D301A; 9, D305A;
10, αIIb/α5(254-353). (B) Cell lysates were immunoprecipitated with B1B5, electrophoresed and
immunodetected with anti-αIIb polyclonal antibody SEW-8 as described in the Materials
and methods section. Lanes as in (A). (C) Lysates were immunoprecipitated with anti-β3 mAb
AP3, electrophoresed and immunodetected with SEW-8 as above. Lanes as in (A).
We examined whether the mutant α-subunits were capable of
complexing with β3 by immunoprecipitating cell lysates with
AP3, an mAb to β3, and detecting with a polyclonal antibody to
αIIb, SEW-8. No protein was detected in either mock-transfected
cells or cells transfected with β3 only. Mature αIIb and a small
amount of pro-αIIb were detected in cells transfected with wild-
type αIIb. When lysates from cells transfected with mutant αIIb
were examined, a band corresponding to pro-αIIb was seen, indi-
cating that mutant pro-αIIb proteins were capable of complexing
with β3. For D301A and D305A, faint bands were seen correspon-
ding to mature αIIb, suggesting that small amounts of these mutant
proteins were being processed (Figure 2C, lanes 1–9).
Expression of flanking region chimaeras
Three chimaeras were constructed in which α5 sequences were
substituted for αIIb sequences in the regions directly flanking
the second calcium-binding domain: αIIb/α5(254-353), a chimaera
that substitutes the sequence from just distal to the first calcium-
binding domain, through the second calcium-binding domain and
immediately up to the beginning of the third calcium-binding
domain with the corresponding sequence of α5; FR1, a chimaera
that substitutes the sequence between the first and second calcium-
binding domains of αIIb with the corresponding sequence of
α5; and FR2, a chimaera that substitutes the sequence between
the second and third calcium-binding domains of αIIb with the
corresponding sequence of α5 (Figure 1B).
No αIIb/α5(254-353)–β3 complex was detected on the cell
surface (Figure 2A, lane 10). When unlabelled cell lysates were
immunoprecipitated with B1B5, only uncleaved pro-αIIb, but not
the mature form, was detected (Figure 2B, lane 10). When the
lysates were immunoprecipitated with AP3 and probed with an
αIIb-specific antibody, the uncleaved form of αIIb/α5(254-353) was
detected, indicating that αIIb/α5(254-353) complexed with β3 (Fig-
ure 2C, lane 10).
Immunoprecipitation of biotinylated cell-surface proteins with
Tab from transiently transfected COS cells expressing FR1 and
FR2 revealed that the α-subunit of each mutant protein was
expressed on the cell surface (Figure 3). For FR2, a similar amount
of β3 co-immunoprecipitated with the FR2 α-subunit, indicating
heterodimer complex formation. Interestingly, almost no β3 co-
immunoprecipitated with the FR1 α-subunit, suggesting either
that FR1 exists on the cell surface as an isolated subunit or that
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Figure 3 Expression and complex formation of FR1 and FR2 in COS cells
Cell-surface proteins were biotinylated and immunoprecipitated with anti-αIIb mAb Tab,
electrophoresed and detected with streptavidin–HRP as described in the Materials and methods
section. 1, WT; 2, FR1; 3, FR2.
Table 1 Antibody binding to stable clones of CHO-transfected cells
Stable cell lines expressing β3, WT, FR1 or FR2 were incubated with anti-αIIb mAb Tab or with
complex-specific mAb AP2, washed and stained with FITC-labelled goat anti-mouse IgG and
analysed by flow cytometry.
Tab AP2 100× AP2 1000× AP2
β3 1.3 2.4 3.2 11.1
WT 411.6 301.3 441.1 541.3
FR1 235.7 24.9 40.3 45.3
FR2 305.0 318.0 – –
Figure 4 Differential co-immunoprecipitation of FR1 with β3 using subunit-
and complex-specific mAbs
Cell-surface proteins from CHO-stable cell lines expressing WT (lanes 1, 3 and 5) or FR1
(lanes 2, 4 and 6) were labelled with biotin and immunoprecipitated with Tab (lanes 1 and 2),
complex-specific mAb AP2 (lanes 3 and 4) or AP3 (lanes 5 and 6), electrophoresed and detected
with streptavidin–HRP.
the non-covalent association between the α- and β-subunits is not
strong enough to survive solubilization and immunoprecipitation.
Stable CHO cell lines expressing FR1 and FR2 were generated
and compared with previously made CHO cell lines expressing
wild-type αIIbβ3, mock-transfected and β3-only transfected
cells. Flow cytometry with Tab showed FR1 and FR2 expression
levels that were 50–75% of wild-type (Table 1). Staining with
AP2, a complex-specific mAb, revealed that wild-type and FR2
expressing cells had nearly equal staining (301 versus 318 arbi-
trary units), but FR1 staining was <10% of wild-type (25 units).
All subsequent experiments were performed using the stable cell
lines.
To investigate further the state of FR1 on the cell surface,
solubilization was performed with a variety of detergents, inclu-
ding Brij96, digitonin and n-octyl glucoside, and in the presence or
absence of calcium, magnesium, manganese or GRGDSF. None
of these conditions significantly increased the amount of β3 that
co-immunoprecipitated with FR1 (results not shown). Similar
results were obtained when immunoprecipitation was performed
with the β3-specific mAb AP3. The wild-type α-subunit co-
immunoprecipitated with β3 in nearly equimolar amounts, but
little or no FR1 was co-immunoprecipitated (Figure 4). When
immunoprecipitation was performed with ten times the normal
Figure 5 Flow-cytometric analysis of cell-surface expression of FR1
subunit- and complex-specific mAbs
Stable cell lines expressing WT (W), FR1 (F) or mock-transfected cells (M) were incubated with
complex-specific mAbs AP2, A2A9, 10E5 or with anti-αIIb mAb Tab, washed and stained
with FITC-labelled goat anti-mouse IgG and analysed by flow cytometry. (A) AP2, (B) A2A9,
(C) 10E5 and (D) Tab.
concentration of AP2, a small amount of FR1β3 complex was
immunoprecipitated, but it only represented a small fraction
of the total FR1 present on the cell surface (Figure 4). These
results suggest the presence of two forms of FR1β3, one that is
recognized by AP2 and one that is not.
Further studies were performed using flow cytometry with seve-
ral complex-specific mAbs. FR1β3 reacted weakly with AP2 and
10E5, but not with A2A9, while reacting strongly with the αIIb-
specific mAb Tab (Figure 5). Incubations were performed with
mAb concentrations that were saturating for cells expressing wild-
type αIIbβ3. For both AP2 and 10E5, only a single population
of FR1β3 was detected, indicating that all cells expressed both
forms of FR1β3, rather than some cells expressing integrin that
recognized the mAbs and some cells expressing integrin that did
not recognize mAbs. Several attempts were made to increase the
amount of binding of AP2 to FR1β3. Incubations with AP2 were
performed at 4, 25 and 37 ◦C for 1, 4 or 24 h in an attempt to trap
the complex in a conformation capable of binding an antibody,
or with antibody at 100- and 1000-fold higher concentrations to
determine if the low antibody binding was due to a decreased
affinity of FR1β3 for AP2. None of these conditions increased
antibody binding to FR1β3 expressing cells by more than a factor
of 2, which was similar to the increase in AP2 binding to wild-type
cells under the same conditions (Table 1 and results not shown),
suggesting a large change in affinity of FR1β3 for AP2 or a lack
of complex formation.
Adhesion studies
As an initial attempt to determine whether FR1 and FR2 had
any change in their function, the ability of wild-type or mutant
integrin-expressing CHO cells to adhere to fibrinogen immo-
bilized on the wells of microtitre plates was examined. CHO cells
constitutively express α5β1, the prototypic fibronectin receptor,
and all three cell lines adhered to fibronectin-coated wells with
similar efficiency (results not shown). Adhesion on fibrinogen
over a 1000-fold concentration range was examined and results
were normalized to adhesion on fibronectin. Adhesion on both
fibronectin and fibrinogen was blocked by GRGDSF (results
not shown). As can be seen in Figure 6, maximal adhesion of
wild-type cells on fibrinogen was approx. 70% of adhesion on
fibronectin and occurred when the coating concentration was
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Figure 6 Comparison of WT, FR1 and FR2 adhesion on fibrinogen
Microtitre plates were coated with 10 µg/ml fibronectin or the indicated concentration or
fibrinogen and blocked with BSA. Cells were allowed to attach for 2 h at 37 ◦C, washed and
the number of bound cells was quantified by staining with Crystal Violet. Background binding
was subtracted (binding to BSA). Adhesion on fibronectin was defined as 100 for each cell line,
and adhesion on fibrinogen was normalized to fibronectin binding. Adhesion on fibronectin was
similar for each cell line. , WT; , FR1; , FR2.
<10 µg/ml fibrinogen. Half-maximal adhesion occurred when
the coating concentration was 3.7 µg/ml fibrinogen. Although
FR1β3-expressing cells adhered normally to fibronectin, they did
not adhere to fibrinogen-coated wells, even when the coating
concentration was 256 µg/ml, nearly 70 times the half-maximal
coating concentration for wild-type cells. Whereas wild-type
cells adhered to fibronectin better than fibrinogen, FR2β3-
expressing cells adhered to fibrinogen even better when compared
with fibronectin. As a result, maximal normalized adhesion of
Figure 7 PAC-1 and fibrinogen binding to FR2 and WT
(A) PAC-1 binding. Specific binding of PAC-1 was measured by incubating cells with LIBS 6-activating antibody either in the presence or absence of 1 mM GRGDSF. FITC–PAC-1 was added at the
indicated final concentration and cells were incubated for 30 min at room temperature, washed, fixed and analysed by flow cytometry. Specific binding was defined as total binding minus ligand
binding in the presence of GRGDSF. , WT; , FR2. MFI, mean fluorescent intensity. Inset: cells were incubated with 10 µg/ml FITC–PAC-1. Black bar, binding in the presence of LIBS 6 and 1 mM
GRGDSF; narrow diagonal lines, binding without addition of LIBS 6; wide diagonal lines, binding in the presence of LIBS 6. (B) Specific binding of fibrinogen was measured by incubating cells
with LIBS 6 activating antibody either in the presence or absence of 1 mM GRGDSP. FITC–fibrinogen was added at the indicated final concentration, and cells were incubated for 30 min at room
temperature, washed, fixed and analysed by flow cytometry. Specific binding was defined as FITC–fibrinogen binding minus FITC–fibrinogen binding in the presence of GRGDSP. , WT; , FR2.
FR2β3 cells on fibrinogen was 164% of wild-type. Half-maximal
adhesion occurred at 1.9 µg/ml fibrinogen, approximately half
that of wild-type.
Soluble ligand binding
We examined the ability of the mutant integrins to bind soluble
ligands. Neither mock-transfected nor β3-only cells were able
to bind soluble ligand when activated with either LIBS 6 or
DTT (results not shown). FR1 was not able to bind to the ligand
mimetic antibody PAC-1 when integrin was activated either with
the activating mAb LIBS 6 or with DTT, whereas both wild-
type and FR2 bound similar amounts of PAC-1 when activated
with LIBS 6 (Figure 7A). Wild-type and FR2 bound only minimal
amounts of PAC-1 in the absence of LIBS 6, demonstrating that the
FR2 chimaera was not in a constitutively active state. FR1 bound
only minimal amounts of fibrinogen even when incubated with
2000 nM fibrinogen, a concentration more than ten times the value
of Kd for fibrinogen for wild-type (results not shown), suggesting
that only the fraction of FR1β3 that was recognized by AP2
was able to bind fibrinogen. Besides fibrinogen, αIIbβ3 can bind
several soluble ligands, including fibronectin [4,5]. We examined
whether FR1 retained the ability to bind fibronectin, even though
its ability to bind fibrinogen was impaired, and determined that
fibronectin binding was impaired in a fashion similar to fibrinogen
binding (results not shown).
FR2 bound fibrinogen in a manner similar to wild-type, but
with higher affinity (Figure 7B). The maximal binding was
statistically identical: 15.2 +− 1.0 and 14.8 +− 0.45 arbitrary units
for wild-type and FR2 respectively. However, FR2 had a higher
affinity for fibrinogen, having a Kd value of 66.2 +− 6.4 nM
versus 148 +− 25 nM for wild-type (P < 0.005). Even though FR2
was a chimaera with α5, which, when complexed with β1,
binds fibrinogen through an RGD sequence [44], the binding
of fibrinogen by FR2 was mediated by the C-terminus of the
fibrinogen γ -chain, as binding was inhibited by antibodies to
the H12 sequence of the γ -chain, but not by antibodies to either
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Figure 8 Inhibition of fibrinogen binding to both WT and FR2 by antibodies
to the γ -chain of fibrinogen, but not by antibodies to the RGD sequences
Cells were incubated with LIBS 6 for 15 min at room temperature. Cells were then incubated
for 30 min at room temperature with 50 nM fibrinogen and 10 µg/ml control or anti-fibrinogen
IgG. Cells were washed and then incubated with FITC-chicken anti-human fibrinogen IgG for
30 min at room temperature, washed, fixed and analysed by flow cytometry. Specific binding
was defined as fibrinogen binding minus binding in the presence of 1 mM GRGDSF peptide.
Specific fibrinogen binding in the presence of control IgG was set at 100. 1, control IgG; 2,
anti-Aα chain N-terminal RGD IgG; 3, anti-Aα chain C-terminal RGD IgG; 4, anti-γ chain
H12 IgG. Inhibition by the anti-γ -chain H12 IgG was significantly different from control IgG
(P < 0.001) in each case.
of the Aα chain RGD sequences (Figure 8). Thus, binding of
fibrinogen to FR2, which is through an RGD mechanism, was
not mediated by α5β1, and substitution of the α5 sequence into
αIIb did not alter the mechanism by which the chimaeric αIIbβ3
bound fibrinogen. Confirming the fibrinogen-binding studies, FR2
formed large aggregates in the presence of fibrinogen when
activated with MnCl2, as did wild-type cells, but FR1 was not
able to form aggregates (results not shown).
Dissociation studies
The αIIbβ3 complex irreversibly dissociates when incubated
with EDTA at 37 ◦C, and subunit dissociation can be monitored
by loss of AP2 binding. We have demonstrated previously a
correlation between the stability of chimaeric αIIbβ3 complexes
and fibrinogen binding: mutants that bound fibrinogen with higher
affinity than wild-type had increased stability, whereas mutants
with lower binding were less stable [24]. We examined the stabi-
lity of FR2β3 complexes compared with wild-type when incu-
bated with 5 mM EDTA at 37 ◦C for 30 min (Figure 9). Wild-type
αIIbβ3 had a dissociation half-time of 2.88 +− 0.80 min, equal
to the previously determined half-time of 2.56 +− 0.07 min [24],
whereas FR2 had a dissociation half-time of 6.55 +− 0.67 min
(P < 0.005).
DISCUSSION
We have previously demonstrated that the second calcium-binding
domain of αIIb could be replaced by the corresponding sequence
of α5 with no measurable effect on expression or function, but
certain point mutations that substituted the α5 sequence for αIIb
within the second calcium-binding domain had subtle effects on
receptor function [24]. In the present study, we constructed a
series of αIIb/α5 chimaeras to study the importance of the regions
Figure 9 Greater resistance to subunit dissociation by EDTA in FR2
compared with WT
Cells were incubated with 5 mM EDTA at 37 ◦C for the indicated time, washed, incubated with
AP2, washed again and incubated with FITC-goat anti-mouse IgG, washed once more, fixed
and then analysed by flow cytometry. Each curve in the Figure is the average of three separate
experiments. , WT; , FR2. MFI, mean fluorescent intensity.
flanking the calcium-binding domain on receptor expression and
function. Calcium-binding domains are regions of high homo-
logy; αIIb and α5 have 80% sequence identity over 34 amino
acids that include the calcium-binding domain and immediate
flanking regions. The remaining 61 amino acids in the region
between the first and second and the second and third calcium-
binding domains, designated FR1 and FR2 respectively, share low
homology. In the β propeller model, the flanking regions occupy
strands C and D of the blade preceding and containing the calcium-
binding domain, regions which are farther from the central axis
and are proposed to accommodate sequence modifications such
as in the alternatively spliced integrins α3, α6 and α7 or, in our
case, the αIIb/α5 chimaeras [15]. The chimaera with the greatest
substitution of α5 sequence, αIIb/α5(254-353), a chimaera that sub-
stituted α5 sequence for αIIb from immediately after the end of
the first calcium-binding domain to the beginning of the third
calcium-binding domain, however, was not expressed on the cell
surface, but complexed with the β3-subunit. In contrast, chimaeras
that substituted individual regions, FR1 or the second calcium-
binding domain or FR2 were expressed on the cell surface.
Two populations of FR1 were expressed on the surface of CHO
cells. The minor one (5–20% of the population recognized by
the αIIb-specific mAb Tab) recognized certain αIIbβ3 complex-
specific mAbs and formed a heterodimer that was stable when
immunoprecipitated, whereas the major one (80–95% of the
total) did not. It is not clear whether the population of FR1 that
did not recognize complex-specific antibodies had undergone a
conformational change that simply ablated the epitope or if the
complex had dissociated. It has been reported that a point mutation
at L264A, which is within the FR1 chimaeric region, resulted in
the expression of αIIbβ3 on the cell surface, but the heterodimer
was not recognized by a variety of antibodies, suggesting that a
major conformational change was induced by the mutation [45].
Although heterodimer formation is required for transport to the
cell surface [10,12,46,47], an unstable αIIbβ3 complex has been
described previously [48].
The presence of two populations of FR1, with presumably the
same amino acid sequence, could be explained by an equilibrium
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Figure 10 Model of a portion of αIIbβ3 depicting the interaction of mutated regions αIIb with β3
Colours of αIIb are as in Figure 1; β355−432, tan; N-linked carbohydrate, large brown balls (for clarity, only the first N-acetylglucosamine subunit is indicated). A red ball indicates a potential N-linked
glycosylation site. Amino acids participating in intersubunit hydrogen-bondings are indicated by ball-and-stick models (dark green, Thr260; light green, Thr264; light violet, Glu322). Hydrogen bonds
are indicated by black dotted lines. Met272 is shown in dark green by a ball-and-stick model. Asp232 of the RGD-binding pocket is indicated in dark red: (A) overview; (B) close-up of amino acids
participating in intersubunit interactions and potential glycosylation sites.
between two states, a properly folded one and an improperly
folded conformation. An alternative explanation of the different
populations is differential glycosylation. The α5 FR1 sequence
contains three potential N-linked glycosylation sites, and the FR1
α-subunit immunoprecipitated with an anti-αIIb-subunit-specific
mAb migrated at a slightly higher apparent molecular mass than
did the subunit immunoprecipitated with a complex-specific mAb,
suggesting differential glycosylation as the probable reason for
the two states. Of the three potential glycosylation sites, the last
one is homologous with one in αV, and would not be expected to
cause conformational problems. Molecular modelling of αIIb and
FR1, based on the crystal structure of αV [16], suggests that the
second potential glycosylation site, an NGS sequence, is mostly
buried, and therefore is probably not utilized. The first potential
glycosylation site, NLT, at amino acids 261–263, is in a loop at
the top of the β-propeller and in contact with the β-subunit. The
residues are mostly exposed and could be utilized. Importantly,
Thr263 is conserved in αv, α5 and αIIb and participates in inter-
subunit hydrogen-bonding (Figure 10). It is also adjacent to the
Leu264 that has been shown to be critical for proper conformation
of the complex [45] and close to Thr260, which also participates in
intersubunit hydrogen-bonding. Additionally, the crystal structure
of αvβ3 reveals that the glycosylation site at Asn320 of the β-sub-
unit is utilized, is close to Asn263 of the α-subunit, and interacts
with the α-subunit through hydrophobic interactions with con-
served Met272. The corresponding sequence in β1 does not have
a glycosylation site, suggesting that to maintain the proper con-
formation of the complex, either the site on the α-subunit or the
β-subunit should be glycosylated, but not both. Glycosylation
has been demonstrated to be essential for stable integrin subunit
association by Zheng et al. [49], who reported that limited
deglycosylation of K562 cells or purified α5β1 in liposomes led
to the formation of an unstable complex that dissociated after
immunoprecipitation. The importance of glycosylation in subunit
interactions has also been recently demonstrated for the formation
of a stable triple-helix structure in collagens [50].
The small amount of ligand bound by FR1 is consistent with
the smaller, presumably properly glycosylated, population which
is recognized by certain function-blocking complex-specific anti-
bodies, as being active, and the larger, improperly glycosylated
population as being inactive. Differential glycosylation has been
shown to affect both the expression level and the ability of
α5β1 and α6β1 to bind to fibronectin and laminin respectively
[51,52].
Whereas the major population of FR1 forms a weak or perturbed
complex with β3, FR2 forms a highly stable complex. The dis-
sociation half-time for FR2 when incubated with EDTA at 37 ◦C is
more than twice that of wild-type αIIbβ3. FR2β3 would appear
to be a ‘super’ αIIbβ3, adhering to fibrinogen better, having a
higher affinity for fibrinogen and being more stable. The FR2
region encompasses three variable loop regions and two highly
conserved strands (Figure 11). The first nine and last four residues
of the FR2 substitution lie in two juxtaposed loops on the top of
the FR2 β-propeller and are within 25 Å (1 Å = 0.1 nm) of the βA
and EGF (epidermal growth factor) domains of β3 in the complex.
In the αVβ3 complex, the first loop makes one hydrogen bond to
the β3-subunit between the side chains of αVQ311 and β3S291.
A glutamic residue is invariant at this position among the RGD
clade (αIIb, αV, α5 and α8) (see Figure 11 and Supplemental Fig-
ure 1, http://BiochemJ.org/bj/379/bj3790449add.htm), and this
interaction is expected to be maintained in the αIIbβ3, α5β1 and
FR2β3 complexes. Although close to the β-subunit, the residues
of the third loop of FR2 are predicted not to make hydrogen
bonds with the β3-subunit. While there are a significant number of
differences between αIIb and α5 in these two loops in FR2 on the
top of the β-propeller, the one hydrogen-bond contact between αV
and β3 in the unliganded complex is, not surprisingly, conserved
within the entire RGD clade. It is possible that substituting the α5
loops for the αIIb loops on the top of the β-propeller might result
in a complex that has higher affinity for fibrinogen and adheres
to fibrinogen better, but it is not at all clear how a substitution in
those loops alone could account for the formation of a more stable
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Figure 11 Model of blades 4–6 of αIIb β-propeller highlighting important conserved and variable amino acids
(A) Blade colours and calcium atoms as in Figure 1. Dark blue CPK model, invariant amino acids; light blue, conserved residues; light plum, highly variable. Conserved large hydrophobic amino
acid at the 7th position of calcium-binding loop 3 is shown by a violet CPK model. The arginine residue at position 7 of the second calcium-binding domain is shown by a dark plum CPK model.
Arginine of loop 2 is shown as light plum. (B) Model rotated by 90◦ about the vertical axis.
complex when incubated with EDTA, since the calcium-binding
sites are on the bottom of the β-propeller.
The second loop in FR2 lies near the second calcium-binding
domain and near the site of our previously reported ‘super’
αIIbβ3, LD (R303H304 → L303D304 mutation at the 7th and
8th positions of the second calcium-binding domain) [24]. The
consensus sequence for the β-hairpin calcium-binding loops
includes a conserved hydrophobic amino acid at the 7th position in
the loop with the carbonyl oxygen of this hydrophobic residue co-
ordinating the calcium atom. This residue is conserved as a large
hydrophobic amino acid across the 2nd, 3rd and 4th calcium-
binding sites in all 19 species of the α-integrins in the RGD clade
for which there is sequence (see Supplemental Figure 2, http://
www.BiochemJ.org/bj/379/bj3790449add.htm). The striking ex-
ception to the consensus sequence is the highly charged arginine
that is found in the 7th position of the second calcium-binding loop
in each of the seven sequenced species of αIIb. Given the strong
conservation of a large hydrophobic residue at the 7th position of
the β-hairpin calcium-binding loop, it is possible that a single-
point mutation of arginine to leucine would also give the same
functional behaviour as FR2 and the RH → LD substitution did.
Since the side chain of the residue at the 7th position is largely
solvent-exposed and can easily tolerate being charged and polar
without major structural changes, it seems probable that the posi-
tively charged side chain acts by destabilizing calcium binding.
Potential serendipitous interactions between the α5 loop 2 se-
quence of FR2 and the arginine residue in the αIIb second
calcium-binding domain could mimic, partially or completely,
the proposed stabilization of calcium binding seen with the LD
substitution. The closest residues to the arginine residue in the
second calcium-binding loop are a proline–arginine in loop 3 in
αIIb. In FR2, these positions are histidine–proline, which may
induce either a conformational change or a change in the electro-
static potential of the second calcium-binding site. This hypothesis
seems reasonable, given the noted importance of bivalent cation
binding on both heterodimer association and high-affinity li-
gand binding [17–19], and is supported further by the constrained
structural relationship of the calcium-binding sites indicated by
the near invariance of the band of residues at the bottom of the
β-propeller (blue balls in Figure 11).
Integrin activation involves global rearrangement of the
structure. The crystal structure of the resting integrin predicts a
‘bent’ conformation, with the ligand-binding site at the interface
of the α- and β-subunits occluded, and activation is supposed
to cause straightening of the molecule. Conflicting models posit
that the head groups separate on activation [53,54] or that the
legs separate [55–57]. As a result of the legs separating, the first
loop of FR2 is modelled such that no contact is made with the
β-subunit. It is possible that changes in the FR2 loop facilitate
breaking of the hydrogen bond between the subunits, but we did
not see either constitutive or increased activation of FR2β3, but
found only increased affinity for fibrinogen.
Our results indicate that the conformation of the second
calcium-binding loop is critical for maturation and cell-surface
expression of αIIbβ3, but not for the formation of the αIIbβ3
heterodimer. Each of the point mutations that we made to calcium
co-ordinating residues in the second calcium-binding domain
blocked expression of the heterodimer on the cell surface, but none
of them blocked interaction with β3. The mutations, however,
altered the complex and the complexes did not undergo normal
post-translational modification. After complex formation, the
nascent heterodimer is normally transported to the trans-Golgi
where cleavage of the α-chain into heavy and light chains occurs
[12,58,59]. Although each of the mutants formed heterodimers,
only pro-αIIb was detected in immunoprecipitates from whole
cell lysates, indicating lack of proteolytic processing in the
Golgi. Recently, two new mutations V298F and I374T that occur
in the second and third calcium-binding domains respectively,
which cause Glanzmann’s thrombasthenia, have been studied
[60]. Similar to the results that we present, both mutations
allowed αIIbβ3 complex formation to occur; however, each
mutation caused decreased, rather than absent, surface expression
of the complex. Molecular modelling predicted the necessity for
branched-chain hydrophobic amino acids at these positions to
maintain the tight β turns necessary for the proper conformation
of the calcium-binding loops.
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In conclusion, we have demonstrated the importance of the
conformation of the second calcium-binding domain for cell-
surface expression of the αIIbβ3, but not for heterodimer
formation, and the surrounding sequences are critical for αIIbβ3
assembly and function.
This study was supported by National Institute of Health grant HL45100.
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